• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Ecor1 Capital, Llc bought $9,999,978 worth of shares (273,972 units at $36.50) (SEC Form 4)

    8/16/24 12:04:31 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANAB alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    EcoR1 Capital, LLC

    (Last) (First) (Middle)
    357 TEHAMA STREET #3

    (Street)
    SAN FRANCISCO CA 94103

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ANAPTYSBIO, INC [ ANAB ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    08/14/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 08/14/2024 P 273,972(2) A $36.5 7,794,996(3) I See Notes(1)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The filers are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund ("the Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold shares directly for the benefit of their investors. EcoR1 may be deemed to beneficially own the shares indirectly as the investment adviser to the Fund, and Mr. Nodelman may be deemed to beneficially own them indirectly as the control person of EcoR1. The filers disclaim beneficial ownership of the shares except to the extent of their pecuniary interest therein.
    2. Qualified Fund purchased all of the shares acquired in this transaction.
    3. After this transaction, Qualified Fund holds 7,316,874 shares of Issuer's Common Stock.
    Oleg Nodelman, Manager of EcoR1 Capital, LLC 08/15/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ANAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANAB

    DatePrice TargetRatingAnalyst
    2/4/2025$25.00Outperform
    Wolfe Research
    12/11/2024$52.00 → $19.00Buy → Neutral
    H.C. Wainwright
    12/2/2024Buy → Neutral
    BTIG Research
    7/22/2024$55.00Buy
    H.C. Wainwright
    7/19/2024$29.00 → $69.00Neutral → Overweight
    JP Morgan
    4/16/2024$47.00Outperform
    Leerink Partners
    4/11/2024$56.00Overweight
    Wells Fargo
    3/12/2024$20.00 → $34.00Neutral → Outperform
    Wedbush
    More analyst ratings

    $ANAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

      SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

      11/14/24 4:00:05 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

      SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

      11/14/24 9:24:47 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by AnaptysBio Inc.

      SC 13D/A - ANAPTYSBIO, INC (0001370053) (Subject)

      8/16/24 12:07:11 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    SEC Filings

    See more
    • SEC Form 10-Q filed by AnaptysBio Inc.

      10-Q - ANAPTYSBIO, INC (0001370053) (Filer)

      5/5/25 4:19:46 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ANAPTYSBIO, INC (0001370053) (Filer)

      5/5/25 4:17:51 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by AnaptysBio Inc.

      SCHEDULE 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

      4/30/25 10:57:53 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wolfe Research initiated coverage on AnaptysBio with a new price target

      Wolfe Research initiated coverage of AnaptysBio with a rating of Outperform and set a new price target of $25.00

      2/4/25 6:58:43 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded AnaptysBio from Buy to Neutral and set a new price target of $19.00 from $52.00 previously

      12/11/24 12:23:14 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio downgraded by BTIG Research

      BTIG Research downgraded AnaptysBio from Buy to Neutral

      12/2/24 6:53:00 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schmid John P. acquired $201,241 worth of shares (11,068 units at $18.18) (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      3/27/25 4:10:12 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schmid John P. exercised 42,337 shares at a strike of $6.50, increasing direct ownership by 1,086% to 46,237 units (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      1/15/25 5:04:11 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Lizzul Paul F. covered exercise/tax liability with 6,597 shares and converted options into 16,700 shares, increasing direct ownership by 65% to 25,643 units (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      1/7/25 5:33:21 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Leadership Updates

    Live Leadership Updates

    See more

    $ANAB
    Financials

    Live finance-specific insights

    See more

    $ANAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Actym Therapeutics Appoints Thomas Smart as CEO

      BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

      4/24/24 9:00:00 AM ET
      $ANAB
      $PGEN
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

      After more than 15 years serving on AnaptysBio's Board of Directors, Jamie Topper, M.D., Ph.D., is stepping down and will serve as an advisor to the Board through Q1 2024 SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors. "We are excited to welcome John to Anaptys' Board of Directors as chairman. With more than 25 years of diverse experience across the biopharmaceutical landscape, John brings a track record of substantial accomplishment across our sector as a biotech CEO a

      9/18/23 4:15:00 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

      Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonistHosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023Announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032, a BTLA agonist, Phase 1 dataInitiating a global Phase 2b trial to treat rheumatoid arthritis in Q3 2023 and a second Phase 2 trial, in an indication to be announced, by year-end 2023 with rosnilimab, a PD-1 agonistReiterating cash runway through year-end 2026 with expected year-end 2023 cash and investments of $370 – $385 million SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage b

      5/11/23 4:15:00 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

      Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the first week of JuneInitial Phase 2 data for rosnilimab in ulcerative colitis (UC) on track for Q4 2025Ongoing Phase 1a trials in healthy volunteers for ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulatorAuthorized a $75 million Stock Repurchase Program in March 2025 and reiterating cash runway through year-end 2027 SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, tod

      5/5/25 4:15:00 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Anaptys Announces Stock Repurchase Plan

      SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company's outstanding common stock, par value $0.001 per share. Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticipates receipt of a $75 million commercial sales milestone payment from GSK in 2025 or 2026. Notwithstanding the potential full execution of the Stock Repurchase Plan, the Company reiterates its previ

      3/24/25 9:15:00 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ecor1 Capital, Llc bought $1,099,642 worth of shares (85,098 units at $12.92) (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      1/2/25 6:17:02 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Ecor1 Capital, Llc bought $9,999,978 worth of shares (273,972 units at $36.50) (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      8/16/24 12:04:31 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care